Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.
Moe Alsumidaie
Advertisement
Articles by Moe Alsumidaie
The FDA’s Dr. John Whyte offers his perspectives on patient centricity and the issues that FDA and industry are facing.
Amidst arguments that industry is heading for another economic recession, Moe Alsumidaie reminds us that biopharma has shown resiliency during such times.
Income and Depression: A Predictive Model for Clinical Trials Patient Dropout
Published: | Updated:
Moe Alsumidaie looks at data collection methods and concepts that can result in predicting patients at risk of dropping out from a clinical trial.
The report analyzed data from several biopharmaceutical and medical device clinical trials, and emphasized several observations
Advertisement
Latest Updated Articles
- Enhancing Racial Diversity in Clinical Trials
Published: September 18th 2013 | Updated: November 15th 2020
- Income and Depression: A Predictive Model for Clinical Trials Patient Dropout
Published: February 22nd 2015 | Updated: November 15th 2020
Will Another Recession Bash the Biopharmaceutical Industry?Published: May 3rd 2016 | Updated: November 15th 2020
FDA’s John Whyte Delves Deeper into Patient CentricityPublished: November 30th 2016 | Updated: November 15th 2020
Emerging Biopharma Tackles the Opioid CrisisPublished: September 12th 2019 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
2
Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion
3
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
4
Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya
5